Technical Analysis for OCGN - Ocugen, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bearish Engulfing | Bearish | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
Parabolic Rise | Strength | 0.00% | |
Earnings Movers | Other | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
MACD Bullish Signal Line Cross | Bullish | -4.63% | |
New 52 Week Closing High | Bullish | -4.63% | |
180 Bullish Setup | Bullish Swing Setup | -4.63% |
Alert | Time |
---|---|
Outside Day | about 18 hours ago |
Down 5% | about 18 hours ago |
Down 3% | about 18 hours ago |
Fell Below Previous Day's Low | about 18 hours ago |
Down 2 % | about 18 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/18/2024
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Eye Ophthalmology Eye Diseases Vision Diabetic Retinopathy Retina Blindness Host Disease Innovative Therapies Retinopathy Graft Versus Host Disease Retinitis Retinitis Pigmentosa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Eye Ophthalmology Eye Diseases Vision Diabetic Retinopathy Retina Blindness Host Disease Innovative Therapies Retinopathy Graft Versus Host Disease Retinitis Retinitis Pigmentosa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.28 |
52 Week Low | 0.345 |
Average Volume | 5,579,692 |
200-Day Moving Average | 0.53 |
50-Day Moving Average | 0.74 |
20-Day Moving Average | 0.97 |
10-Day Moving Average | 0.98 |
Average True Range | 0.11 |
RSI (14) | 60.47 |
ADX | 35.44 |
+DI | 35.09 |
-DI | 11.98 |
Chandelier Exit (Long, 3 ATRs) | 0.96 |
Chandelier Exit (Short, 3 ATRs) | 1.01 |
Upper Bollinger Bands | 1.11 |
Lower Bollinger Band | 0.82 |
Percent B (%b) | 0.72 |
BandWidth | 30.30 |
MACD Line | 0.09 |
MACD Signal Line | 0.09 |
MACD Histogram | -0.001 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.35 | ||||
Resistance 3 (R3) | 1.37 | 1.30 | 1.29 | ||
Resistance 2 (R2) | 1.30 | 1.22 | 1.28 | 1.27 | |
Resistance 1 (R1) | 1.16 | 1.17 | 1.13 | 1.14 | 1.26 |
Pivot Point | 1.09 | 1.09 | 1.07 | 1.07 | 1.09 |
Support 1 (S1) | 0.95 | 1.01 | 0.92 | 0.93 | 0.80 |
Support 2 (S2) | 0.88 | 0.96 | 0.86 | 0.79 | |
Support 3 (S3) | 0.74 | 0.88 | 0.77 | ||
Support 4 (S4) | 0.72 |